GRPH News and Press, Graphite Bio Inc. From 03/23/22

Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company focused on developing therapies that harness targeted gene integration to treat or cure serious diseases, today announced the formation of its Scientific Advisory Board (SAB), which is initially co...

Wall Street resumed its recent upswing on Tuesday, led by a 2% rise in the Nasdaq, which closed above 14,000 for the first time since mid-February. The rally came amid a surge in bond yields, with investors adding risk to their portfolios in a scramble for higher returns. As an example of the...

Gainers: JX Luxventure (LLL) +214%. Draganfly (DPRO) +83%. Zhangmen Education (ZME) +64%. Antelope Enterprise Holdings Limited (AEHL) +37%. Society Pass (SOPA) +31%. Ever-Glory International Group (EVK) +33%. iQIYI (IQ) +26%. Alzamend Neuro (ALZN) +23%. FreightCar America (RAIL) +24%. Puxin (...

Graphite Bio (GRPH -14.4%) is trading lower for the third straight session after Morgan Stanley downgraded the gene-editing firm to Equal Weight from Overweight, citing a delay for a key data readout for the company’s sickle cell disease candidate, GPH101. Releasing its Q4 2021 financi...

Gainers: TCR2 Therapeutics (TCRR) +16%. Precision BioSciences (DTIL) +16%. Alzamend Neuro (ALZN) +15%. BioSig Technologies (BSGM) +13%. Applied Therapeutics (APLT) +13%. Losers: ORIC Pharmaceuticals (ORIC) -29%. Applied Genetic Technologies (AGTC) -28%. NeuroSense Therapeutics (NRSN...

The clinical-stage gene-editing firm Graphite Bio (GRPH -16.7%) has recorded the biggest intraday loss in more than a month to reach a new post-IPO low after the company pushed back a major data readout for its sickle cell disease candidate, GPH101. Announcing its fourth-quarter financials fo...

The war in Ukraine and the related geopolitical consequences continued to roil markets during Monday's midday action. As part of this process, a spike in aluminum prices sparked a double-digit percentage move in Alcoa (NYSE:AA). Turning to more mundane Wall Street headlines, Blackberry (BB) g...

Gainers: NeuroSense Therapeutics (NRSN) +289%. Yumanity Therapeutics (YMTX) +36%. Dermata Therapeutics (SERA) +30%. Sera Prognostics (DRMA) +21%. Creative Medical Technology Holdings (CELZ) +20%. Losers: Vallon Pharmaceuticals (VLON) -70%. Connect Biopharma Holdings (CNTB) -22%. Imm...

Graphite Bio press release (NASDAQ:GRPH): Q4 GAAP EPS of -$0.35 misses by $0.09. $378.7 million in cash, cash equivalents and restricted cash as of December 31, 2021; cash runway extended into the fourth quarter of 2024 Shares +3.45% PM. For further details see: Graphite Bio GAAP EPS of...

Patient enrollment in Phase 1/2 CEDAR clinical trial of GPH101 for sickle cell disease ongoing at multiple sites; dosing of first patient now planned for second half of 2022, with initial proof-of-concept data anticipated in 2023 Prioritized R&D to maximize capabilities of...